ArticleClinical medicine (London, England)2026
Parvovirus B19-associated fat embolism syndrome in sickle cell disease: A report of two cases.
Article in Clinical medicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hypertension: A common, yet poorly managed condition. What can we do better?Clinical medicine (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fat embolism syndrome (FES) is a rare but likely underdiagnosed complication of sickle cell disease (SCD) characterised by multi- or single-organ involvement secondary to embolism of fat and/or necrotic bone marrow. It is one of the most devastating acute complications of SCD and historically the diagnosis has often been made on the basis of post-mortem findings. Literature on FES in SCD is scarce, although most reported cases are individuals with non-HbSS genotypes for reasons which have not yet been fully elucidated. Even fewer data exist regarding the potential association with parvovirus B19 (B19V) and the mechanisms by which B19V infection could trigger FES in SCD. Management is largely supportive, with early intensive care team involvement for close monitoring and potential organ support. Emerging evidence, albeit limited, suggests that early exchange transfusion has an important role in improving clinical outcomes. We describe two life-threatening cases of FES in patients with SCD of differing genotypes, who required intensive care unit admission but who both recovered with supportive management and early exchange transfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.